EX-99.1 2 ea030557001ex99-1.htm PRESS RELEASE, DATED SEPTEMBER 15, 2026 Exhibit 99.1 Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development TARPON SPRINGS, Fla., September 15, 2026 - Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121) - a differentiated, dual PARP and WNT pathway inhibitor - today announced that the Japan Patent Office (JPO) has granted a key patent covering Allarity’s proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic. The newly granted patent, Japanese Patent No. 7917283, provides protection in Japan into 2039. Thomas Jensen, Chief Executive Officer of Allarity Therapeutics, said: “Japan is one of the world’s largest pharmaceutical markets and is also the home of Eisai, the original developer of stenoparib. This award of the patented patent is critical to securing stenoparib’s developability in one of the world’s most important pharmaceutical markets. This award reflects our ongoing strategic efforts to strengthen and extend our intell…
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
Allarity Therapeutics, Inc.
Other Events
Item 8.01 Other Matters. On September 15, 2026, Allarity Therapeutics, Inc. (the “Company”) announced that the Japan Patent Office had granted a key patent covering the Company’s proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Company context
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is developing stenoparib, a novel PARP/tankyrase inhibitor for patients with advanced ovarian cancer, and is using its proprietary DRP® technology to develop a companion diagnostic designed to identify patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s principal operations are located in Denmark, and its U.S. business address is in Florida. For more information, visit www.allarity.com.